Published in Epidemiology on May 01, 2017
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (2008) 6.87
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med (2014) 6.51
Marginal structural models as a tool for standardization. Epidemiology (2003) 4.52
Metformin in breast cancer: time for action. J Clin Oncol (2009) 3.81
Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle (2009) 3.77
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther (2010) 2.93
Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study. BMJ (2011) 2.80
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Diabetes mellitus and breast cancer. Lancet Oncol (2005) 2.34
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst (2014) 2.17
Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res (2010) 1.70
Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control (2007) 1.66
Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care (2007) 1.56
Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev (2010) 1.55
The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res (2012) 1.53
Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care (2011) 1.52
Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer (2011) 1.48
Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One (2012) 1.43
Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat (2012) 1.27
Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat (2012) 1.20
Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care (2014) 1.08
Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control (2012) 1.00
Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. Gynecol Endocrinol (2012) 0.98
Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin. Diabetes Care (2013) 0.97
The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep (2015) 0.93
Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab (2012) 0.93
The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol Rep (2011) 0.90
Colorectal cancer after start of nonsteroidal anti-inflammatory drug use. Am J Med (2006) 0.86
Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk. ISRN Endocrinol (2013) 0.83
Statin strikeout. N Engl J Med (2014) 0.79
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA (2012) 5.90
Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis*. Crit Care Med (2014) 5.89
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol (2006) 4.70
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2005) 4.55
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care (2005) 3.93
Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol (2012) 3.63
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Lifetime risk of stress urinary incontinence or pelvic organ prolapse surgery. Obstet Gynecol (2014) 3.18
Use of qualitative methods in published health services and management research: a 10-year review. Med Care Res Rev (2010) 3.03
Confounding control in healthcare database research: challenges and potential approaches. Med Care (2010) 3.01
Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab (2009) 2.96
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab (2003) 2.46
Will hypertension performance measures used for pay-for-performance programs penalize those who care for medically complex patients? Circulation (2009) 2.44
1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care (2006) 2.44
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med (2008) 2.40
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31
Evidence of sample use among new users of statins: implications for pharmacoepidemiology. Med Care (2014) 2.22
Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab (2014) 2.18
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol (2014) 2.11
Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum (2006) 1.94
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care (2013) 1.79
Prescription opioid use among older adults with arthritis or low back pain. Arthritis Rheum (2006) 1.77
Opioid analgesics and the risk of fractures in older adults with arthritis. J Am Geriatr Soc (2011) 1.76
The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf (2011) 1.74
Case-control study supports extension of surveillance interval after colonoscopic polypectomy to at least 5 yr. Am J Gastroenterol (2007) 1.74
Prevention or delay of type 2 diabetes. Diabetes Care (2004) 1.73
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Doubly robust estimation of causal effects. Am J Epidemiol (2011) 1.66
Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med (2012) 1.64
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes (2013) 1.62
Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. Am J Epidemiol (2009) 1.60
Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy. JAMA Intern Med (2013) 1.60
The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab (2011) 1.60
Trends in use of surgical mesh for pelvic organ prolapse. Am J Obstet Gynecol (2012) 1.57
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf (2012) 1.56
Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals. Environ Health Perspect (2008) 1.53
Nonexperimental comparative effectiveness research using linked healthcare databases. Epidemiology (2011) 1.50
The role of the c-statistic in variable selection for propensity score models. Pharmacoepidemiol Drug Saf (2010) 1.45
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2007) 1.44
Provider delay among patients with breast cancer in Germany: a population-based study. J Clin Oncol (2003) 1.41
Baseline data from American Society for Metabolic and Bariatric Surgery-designated Bariatric Surgery Centers of Excellence using the Bariatric Outcomes Longitudinal Database. Surg Obes Relat Dis (2010) 1.40
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst (2012) 1.39
Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care (2013) 1.36
Confounder summary scores when comparing the effects of multiple drug exposures. Pharmacoepidemiol Drug Saf (2010) 1.31
Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant. PLoS One (2012) 1.30
Completeness of prescription information in US commercial claims databases. Pharmacoepidemiol Drug Saf (2013) 1.23
Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis (2011) 1.17
Potential for colorectal cancer prevention of sigmoidoscopy versus colonoscopy: population-based case control study. Cancer Epidemiol Biomarkers Prev (2007) 1.16
Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care (2012) 1.11
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J (2008) 1.11
Effect of statin use on acute kidney injury risk following coronary artery bypass grafting. Am J Cardiol (2012) 1.10
Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol (2002) 1.10
Nocturnal sleep duration and cognitive impairment in a population-based study of older adults. Int J Geriatr Psychiatry (2010) 1.10
Patterns of rotavirus vaccine uptake and use in privately-insured US infants, 2006-2010. PLoS One (2013) 1.09
Association of cardiac and vascular changes with ambient PM2.5 in diabetic individuals. Part Fibre Toxicol (2010) 1.07
Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med (2005) 1.06
National Diabetes Data Group vs Carpenter-Coustan criteria to diagnose gestational diabetes. Am J Obstet Gynecol (2011) 1.05
Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf (2013) 1.05
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults. Cancer (2011) 1.04
A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab (2009) 1.04
Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf (2010) 1.02
Obesity and adult asthma: potential effect modification by gender, but not by hay fever. Ann Epidemiol (2008) 1.02
Sling revision/removal for mesh erosion and urinary retention: long-term risk and predictors. Am J Obstet Gynecol (2012) 1.02
Hospitalization and skilled nursing care are predictors of influenza vaccination among patients on hemodialysis: evidence of confounding by frailty. Med Care (2013) 1.01
Comparison of SEER Treatment Data With Medicare Claims. Med Care (2016) 1.01
A framework for understanding cancer comparative effectiveness research data needs. J Clin Epidemiol (2012) 1.00
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res (2011) 0.98
The future of epidemiology. Acad Med (2009) 0.98
Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol (2012) 0.98